NCT05624138View on ClinicalTrials.gov

The Possible Protective Role of Ketotifen Against Oxaliplatin Induced Peripheral Neuropathy

PHASE3RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

November 9, 2022

Primary Completion Date

April 4, 2024

Study Completion Date

June 30, 2025

Conditions
Neuropathy;Peripheral
Interventions
DRUG

Placebo tablets

12 cycles of modified FOLFOX-6 regimen (Oxaliplatin, Fluorouracil, calcium leucovorin) with 2 mg placebo tablets

DRUG

Ketotifen Oral Tablet

ketotifen is a potent anti histaminic drug that may prevent oxaliplatin induced peripheral neuropathy and mucositis and will be administered 2 mg daily along with the 12 cycles of modified Folfox-6 regimen

Trial Locations (1)

31511

RECRUITING

Oncology department Tanta university, Tanta

All Listed Sponsors
lead

Tanta University

OTHER